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Long term immunogenicity following a booster dose of the
inactivated Japanese encephalitis vaccine IXIARO®, IC51
K.L. Dubischar-Kastner1,∗, S. Eder1, T. Jelinek2, B. Jilma3,
A. Kaltenboeck1, H. Kollaritsch4, E. Schuller1, C. Klade1
1 Intercell AG, Vienna, Austria
2 Berlin Center for Travel & Tropical Medicine, Berlin, Ger-
many
3 Medical University Vienna, Vienna, Austria
4 Medical University of Vienna, Vienna, Austria
Background: IXIARO (JESPECT® in Australia, IC51), Inter-
cell’s recently approved Vero cellderived, inactivated
Japanese Encephalitis vaccine, has been proven immuno-
genic and safe in a 0/ 28 Day primary immunization schedule
in adults. Neutralizing antibody titers decline with time and
booster doses are likely needed to obtain a longer last-
ing immune response. Objectives: To assess the effect of
a booster dose on neutralizing antibody titers for up to 12
months after the booster.
Methods: In this open-label phase III trial, 198 sub-
jects, who had received their primary immunization in a
preceding randomized trial, were boosted with IXIARO 15
months after the primary immunization and followed up for
12 months. Neutralizing antibody titers were assessed by
plaque-reduction neutralization test, PRNT on the day of
boosting and 1, 6 and 12 months later. A PRNT50≥ 1:10 was
the cut-off for seroconversion. Systemic and local tolerabil-
ity were solicited with diaries for a 7 days period following
the booster.
Results: Prior to the booster, 69.2% (137/198) of subjects
had PRNT50 titers of ≥1:10. The seroconversion rate (SCR)
was 100% (198/198) one month after the booster. Both at 6
months and 12 months after the booster, the SCR remained
high at 98.5% (194/197 and 191/194 subjects, respectively).
GMTs were 22.5 before the booster and 900, 487 and 361 at
1, 6 and 12 months after the booster. During 7 days after the
booster, 30.8% of subjects reported solicited local reactions,
and 23.2% reported solicited systemic adverse events.
Conclusion: An IXIARO booster 15 months after primary
immunization induced higher neutralizing antibody titers
than seen immediately after primary immunization (a mean
5.3- fold increase). The GMTs and SCRs remained at high lev-
els for 12 months after the booster. A booster dose of IXIARO
was generally well tolerated with a safety proﬁle in line with
the primary immunization.
doi:10.1016/j.ijid.2010.02.615
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Cost effectiveness of Pneumovax® 23 stockpile to prevent
secondary pneumococcal infections among a high-risk
population in the United States during an inﬂuenza pan-
demic
P. Dhankhar1,∗, J. Grabenstein2, M. O’Brien2, E.J. Dasbach11 Merck & Co. Inc., North Wales, PA, USA
2 Merck & Co. Inc., West Point, PA, USA
Background: Recent literature concludes that secondary
bacterial infections (especially pneumococcal infections)
m
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ere the leading cause of death during prior inﬂuenza pan-
emics. One strategy to prevent pneumococcal infections
n adults during a future pandemic is to stockpile 23-valent
neumococcal polysaccharide vaccines.
Methods: We developed a model to estimate the health
nd economic impact of a stockpile of Pneumovax® 23
o prevent secondary bacterial infections among high-
isk adults in the age group 18-64 during an inﬂuenza
andemic. We used the model to project the num-
er of pneumococcal cases, hospitalizations, deaths, and
ays of work loss averted. To measure the incremental
ost-effectiveness ratio (ICER), we used the cost per quality-
djusted life year (QALY) metric. We used remaining life
xpectancy of the population following the pandemic as
he analytic horizon. Two pandemic scenarios were exam-
ned to assess differing pandemic severities: 1918 and
958/68. We included the impact of other interventions
lso, such as prepandemic inﬂuenza vaccines, antivirals,
on-pharmacologic interventions, and herd immunity to
neumococcal disease from use of 7-valent pediatric pneu-
ococcal conjugate vaccine (PCV7). Finally, we examined
he impact of Pneumovax® 23 shelf-life, likelihood of a pan-
emic, and stockpile management on the cost-effectiveness
atio.
Results: Under a 1918-type scenario, based on a pop-
lation of 20 million high-risk adults, a Pneumovax® 23
accination program is projected to avoid 185,000 days of
ork loss, 12,100 pneumococcal cases, 1,690 hospitaliza-
ions, and 3,592 deaths. Under a 1958/68 scenario, the
neumovax® 23 vaccination is projected to avert 40,000
ays of work loss, 7,431 pneumococcal cases, 143 hospi-
alizations and 461 deaths. The cost-effectiveness ratios
ICERs) for the Pneumovax® 23 stockpile compared to no
tockpile under the 1918 and 1958/68 scenarios are $4,661
nd $83,039 per QALY respectively. The ICER for Stockpiling
neumovax® 23 increases as the likelihood of a pandemic
ecreases. Given a ﬁxed shelf life of Pneumovax® 23, the
roportion of stockpile that can be put in the mainstream
se every year also affects the ICERs.
Conclusion: Stockpiling Pneumovax® 23 can be a cost-
ffective strategy for reducing the health and economic
urden of pandemic inﬂuenza in the high-risk U.S. popu-
ation.
oi:10.1016/j.ijid.2010.02.616
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ost-effectiveness of the use 23-valent pneumococcal
olysaccharide vaccine to prevent secondary bacterial
nfections related to pandemic inﬂuenza in Brazil
. O’Brien1,∗, P. Dhankhar2, J. Grabenstein1, E.J. Dasbach2
Merck & Co. Inc., West Point, PA, USA
Merck & Co. Inc., North Wales, PA, USA
Background: Secondary bacterial infections contributed
o a signiﬁcant number of deaths during prior inﬂuenza pan-
emics, and have also been shown to be associated with
ortality during the 2009 H1N1 pandemic. The speciﬁc aim
f this analysis was to assess the costeffectiveness of using
3-valent Pneumococcal Polysaccharide Vaccine (PPV23) at
he beginning of or during an inﬂuenza pandemic to prevent
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econdary bacterial infections among two cohorts of adults
n Brazil.
Methods: We created an initial decision model to eval-
ate the cost-effectiveness of PPV23 used as part of a
omprehensive pandemic plan in the United States. This
odel was adapted to reﬂect cost data from Brazil. Two
ohorts of 6 million Brazilian adults, aged 20-64, were
odeled: high-risk adults and critical workers. The model
ompares costs and disease outcomes associated with two
accination scenarios: PPV23 vaccination and no PPV23
accination. Outcomes are based on attack rates from
wo prior pandemic types: severe (1918) and moderate
1957/1968). PPV23 effectiveness was assumed to be 59%.
accine costs consisted of dose and administration costs.
osts are reported in 2008 Brazilian reals. Cost effective-
ess results are reported as incremental cost effectiveness
atios (ICER) using reals per Quality Adjusted Life Year
QALY).
Results: Under the assumption that no pandemic
nﬂuenza vaccine is available, PPV23 could prevent approx-
mately 15,000 pneumococcal disease cases in the high-risk
opulation during a severe pandemic and 9,000 cases dur-
ng a moderate pandemic. Among 6 million high-risk adults,
he ICERs comparing the PPV23 vaccination scenario ver-
us no PPV23 were estimated to be 1,700 reals per QALY
or a severe pandemic and 18,000 reals per QALY for a
oderate pandemic. Among 6 million critical workers aged
0-64, PPV23 could prevent 64,000 missed work days during
severe pandemic and 17,000 missed work days during a
oderate pandemic.
Conclusion: The cost effectiveness ratios for mass vac-
ination of high risk individuals as well as critical workers
sing PPV23 in Brazil to prevent secondary bacterial infec-
ions related to pandemic inﬂuenza fall within the range
enerally considered to be cost-effective; however, the
ost-effectiveness ratios depend on the severity of the pan-
emic.
oi:10.1016/j.ijid.2010.02.617
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mpact study of hepatitis B vaccination in Sikkim - A north
astern state of India
. Verma ∗, V. Gupta
Sikkim Manipal Institute of Medical Sciences, Gangtok,
IKKIM, India
Background: Sikkim is a small state of India which
ntroduced hepatitis B vaccination into its immunization
chedule. Sikkim is the ﬁrst state of India to introduce Hep-
titis vaccination in the year 2004. Hepatitis B coverage for
he state of Sikkim is approximately 10,000 children per year
nd immunization is done at 6, 10 and 14 weeks of age.
ooster dose has not been incorporated in the immunization
chedule. Since the time of introduction of immunization
o impact study has been done in the vaccinated children.
hether the children being vaccinated mount an adequate
ntibody response against the vaccine needs to be investi-
ated. An attempt was made to study the anti-HBs levels in
cross sectional study of children who received the vacci-
ation against Hepatitis B.
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Methods: 160 post vaccinated children and adolescents
ere included in the study. Only those who had completed
hree doses of the vaccination were included. Serum col-
ected was tested using a commercially available sandwich
LISA kit. The quality control criteria were fulﬁlled and the
ata was analyzed. Anti-HBs Levels below 10mIU/ml were
onsidered as non responders and levels above 10mIU/ml
ere considered as responders.
Results: 53.1% of the participants were males and 46.9%
ere females. Analysis of data revealed that 64.4% of the
opulation under study were responders and 35.6% were
on responders. Female participants who were non respon-
ers were greater than males (38.6%: 32.9%). No signiﬁcant
elation between age and response was seen.
Conclusion: The percentage of non-responders in the post
accination children was signiﬁcantly higher as compared
o most studies conducted in other countries. No study has
een done in India to see the impact of vaccination in chil-
ren. Females seem to be non responders as compared
o males contrary to some studies. Further studies need
o be conducted to investigate the cause of this anomaly.
resuming that India is on the verge of introducing uni-
ersal vaccination against HBV, preparedness to encounter
he problem of non responders to vaccination needs to be
ddressed and a strategy developed to counter it.
oi:10.1016/j.ijid.2010.02.618
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vaccine derived poliovirus case in an immunocompro-
ised argentinian child
.E. Burgos1,∗, S. Elkik1, P. Barbosa1, M. Oleastro1, C.
reire2, A. Parra1, M. Caparelli 3, C. Sarkis4
Hospital Garrahan, Buenos Aires, Argentina
Servicio de Neurovirosis Dpto. Virología. IENEI-NLIS ‘‘Dr.
arlos G. Malbran’’, Buenos Aires, Argentina
Ministerio de Salud, Buenos Aires, Argentina
Hospital Garrahan, Capital Federal, Argentina, Argentina
Background: Although poliomyelitis caused by wild-type
oliovirus has been almost eradicated, especially in devel-
ped countries, vaccine associated paralytic poliomyelitis
VAPP) cases still continue to occur in Latin American coun-
ries. In Argentina, where OPV routine immunization policy
s ongoing, the last wild poliovirus (WPV) case was registered
n 1984. Since then, the several polio cases reported were
APP and Vaccine Derived Poliovirus (VDPV) (ﬁrst iVDPV case
as detected in 1998).
Methods: To report a polio case caused by a VDPV in an
mmunodeﬁcient patient diagnosed with polyclonal agam-
aglobulinemia.
Results: In May 2009 a 15 month-old patient was hospi-
alized in our institution for acute ﬂaccid monoparesis in his
eft lower limb with areﬂexia, with residual paralysis 60 days
fter onset. The patient had a history of recurrent infections
sepsis meningitis and pneumonia).Vaccination calendar was
ompleted for his age (DPt/Hib-HB & OPV: 3 doses). The
hild received OPV3, 8 months before. LCR 8 cells/prot
5mg/100mL/Glu 50mg/ml with negative cultures (bac-
eria -mycobacterium, fungi). EMG showed pre-ganglionic
njury. Spine MRI showed focal intramedullary cone and
